Annual report pursuant to Section 13 and 15(d)

Note 14 - Stockholders' Equity (Tables)

v3.24.1
Note 14 - Stockholders' Equity (Tables)
12 Months Ended
Dec. 31, 2023
Notes Tables  
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]
               

Shares Subject to Purchase

 

Exercise Price per Share

   

Expiration Date

   

at December 31, 2023

 
$ 1.90       1/22/2024       6,372  
$ 1.38       7/17/2028       363,860  
$ 1.25       8/4/2028       205,761  
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]
   

Year ended December 31,

 
   

2023

   

2022

 

Cost of product sales

  $ 130     $ 104  

Research and development cost

    57       36  

General and administrative expense

    2,347       2,115  

Total

  $ 2,534     $ 2,255  
Share-based Payment Arrangement, Option and Restricted Stock Unit, Activity [Table Text Block]
           

Options Outstanding

   

RSUs Outstanding

 
                   

Weighted-

           

Weighted-

 
   

Number of

           

Average

           

Average

 
   

Shares

           

Exercise

           

Grant Date

 
   

Available for

   

Number of

   

Price Per

   

Number of

   

Fair Value

 
   

Grant

   

Shares

   

Share

   

RSUs

   

Per Share

 

Balance at December 31, 2021

    1,668,001       1,026,712     $ 4.44       5,246,875     $ 1.07  

Authorized

    7,000,000                          

Granted

    (3,691,202 )                 3,691,202       0.69  

Exercised/ Released

                      (2,297,130 )     0.90  

Forfeited

    285,455       (32,445 )     5.78       (253,010 )     1.16  

Balance at December 31, 2022

    5,262,254       994,267       4.40       6,387,937       0.91  

Authorized

                             

Granted

    (5,110,852 )                 5,110,852       0.85  

Exercised/ Released

                      (2,676,931 )     0.99  

Forfeited (1)

    321,634       (994,267 )     4.40       (167,367 )     0.92  

Returned to Plan

    947,418                          

Balance at December 31, 2023

    1,420,454                   8,654,491     $ 0.86  
           

Weighted-

 
           

Average

 
           

Grant Date

 
   

Number of

   

Fair Value Per

 
   

Shares

   

Share

 

Outstanding at January 1, 2023

           

Granted

    475,282       0.56  

Outstanding at December 31, 2023

    475,282       0.56  
Share-Based Payment Arrangement, Option, Exercise Price Range [Table Text Block]
   

2023

 

Volatility

    91.40 %

Risk-free interest rate

    4.30 %
Disclosure of Share-Based Compensation Arrangements by Share-Based Payment Award [Table Text Block]
   

Number of Shares

 

Equity Plan

       

Subject to outstanding restricted shares

    8,654,491  

Available for future grants

    1,420,454  

Officer and Director Purchase Plan

    237,382  

Warrants

    575,993  

2022 Employee Stock Purchase Plan

    807,287  

Total reserved shares

    11,695,607